Is GT Biopharma Inc (GTBP) overvalued? · $17.4M cap
GT Biopharma Inc (GTBP) is a biotechnology company listed on NASDAQ.
This page asks whether GT Biopharma Inc (GTBP) looks expensive on cached numbers — not a short thesis.
No cached income statement for GTBP, so there is no earnings base to call rich or cheap.
GTBP currently screens at market cap $17.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next GTBP 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the GTBP stock page for the full model, not this heading.
Not investment advice.